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Abstract
 
A single embryonic stem cell (ESC) line can be repetitively cryopreserved, thawed, expanded,
and differentiated into various cellular components serving as a potentially renewable and well-
characterized stem cell source. Therefore, we determined whether ESCs could be used to
reconstitute  marrow and blood in major histocompatibility complex (MHC)-mismatched
mice. To induce differentiation toward hematopoietic stem cells (HSCs) in vitro, ESCs were
cultured in methylcellulose with stem cell factor, interleukin (IL)-3, and IL-6. ESC-derived,
cytokine-induced HSCs (c-kit
 
 
 
/CD45
 
 
 
) were isolated by flow cytometry and injected either
intra bone marrow or intravenously into lethally irradiated MHC-mismatched recipient mice.
From 2 wk to 6 mo after injection, the peripheral blood demonstrated increasing ESC-derived
mononuclear cells that included donor-derived T and B lymphocytes, monocytes, and granu-
locytes without clinical or histologic evidence of graft-versus-host disease (GVHD). Mixed
lymphocyte culture assays demonstrated T cell tolerance to both recipient and donor but intact
third party proliferative responses and interferon 
 
  
 
production. ESCs might be used as a renewable
alternate marrow donor source that reconstitutes hematopoiesis with intact immune respon-
siveness without GVHD despite crossing MHC barriers.
Key words: embryonic stem cells • hematopoiesis • in vivo • tolerance • mouse
 
Introduction
 
Hematopoietic stem cells (HSCs) obtained from the marrow
or peripheral blood are being used worldwide to treat malig-
nancies, inborn errors of metabolism, and autoimmune
diseases (1–3). Attempts to maintain HSCs in culture for
even relatively short periods of time are unsuccessful due to
terminal differentiation. In addition, GVHD is a common
morbid and/or lethal complication of allogeneic HSC
transplantation (4, 5). HSC graft composition including the
number of T cells, dendritic cells, B cells, and CD34
 
  
 
or
other progenitor cells, as well as bacterial contamination,
varies depending on patient, source, and harvesting tech-
nique. This has resulted in intra-institutional and inter-
institutional variation in graft composition. For these reasons,
a renewable source of HSCs that is not complicated by
GVHD and does not have interpatient, intrapatient, or lot
variability would be desirable.
Embryonic stem cell (ESC) lines are derived from the inner
cell mass of the blastocyst and are totipotent and immortal.
ESCs can be expanded ex vivo as undifferentiated cells that
retain a normal karyotype or, alternatively, can be differen-
tiated ex vivo into cell types of all three germ layers (6, 7).
Leukemia inhibitory factor (LIF) is required to maintain
the undifferentiated state of mouse ESCs, whereas with-
drawal of LIF initiates the formation of embryoid bodies
(EB) and cellular differentiation (8, 9). When EB are cultured,
cells with hematopoietic progenitor phenotype are routinely
observed in vitro (10–14). In the absence of cytokines or
stromal cells, multilineage hematopoietic precursors might
be detected by colony-forming assays after 4 d of EB culture.
C-kit (stem cell factor [SCF] receptor) and CD45 (a hemato-
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poietic lineage marker) expression occur simultaneously on
day 10 of EB culture (15). One challenge for developing
cell therapies from ESCs is whether newly formed tissues
can adapt to function effectively in vivo when transplanted
into an adult (16). Herein, we demonstrate that murine
ESCs induced to differentiate toward c-kit
 
  
 
CD45
 
  
 
HSCs
by removal of LIF and addition of SCF, IL-3, and IL-6 re-
constitute hematopoiesis in lethally irradiated MHC-mis-
matched mice. This occurs without clinical or histological
evidence of GVHD and with bidirectional host/donor tol-
erance and intact third party immune responses.
 
Materials and Methods
 
ESCs
 
The 129/SvJX129/SV-CP F1 (MHC H2
 
b
 
) hybrid, 3.5-d
mouse blastocyst–derived ESC line R1 was provided by A. Nagy
(Mount Sinai Hospital, Toronto, Canada). To maintain ESCs in
an undifferentiated state they were cultured on gelatinized tissue
culture dishes in high glucose Dulbecco’s modified Eagle’s me-
dium supplemented with 15% FBS, 2 mM 
 
l
 
-glutamine, 0.1 mM
 
 
 
-mercaptoethanol, 1
 
  
 
nonessential amino acids, 1
 
  
 
sodium
pyruvate, and 1,000 U/ml LIF (Specialty Media and StemCell
Technologies Inc.). Mitomycin C–treated primary embryonic fi-
broblasts (StemCell Technologies Inc.) were used as a feeder
layer for a long-term culture of R1 ESCs.
 
Induction of ESCs toward Hematopoietic Progenitors (HSCs)
 
To induce differentiation toward HSCs in vitro, the ESCs
were cultured on low adherent Petri dishes in Iscove’s modified
Dulbecco’s medium containing 
 
 
 
1% methylcellulose, 15% FBS,
150 
 
 
 
M monothioglycerol, 2 mM 
 
l
 
-glutamine, 500 ng/ml mu-
rine SCF, 46 ng/ml human IL-3, and 500 ng/ml human IL-6
(StemCell Technologies Inc. and Sigma-Aldrich; cytokines were
provided by Kirin Brewery). Cells were cultured at 37
 
 
 
C in 5%
CO
 
2
 
 
atmosphere incubator for 7–10 d. The single cell suspension
was collected, washed, and suspended in PBS 10
 
7 
 
cells/0.2 ml for
i.v. injection or 0.5 
 
  
 
10
 
7 
 
cells/30 
 
 
 
l in the case of intra bone
marrow (IBM) injection.
 
Flow Cytometric Analysis
 
Two or three color cell cytometric analysis was performed us-
ing standard procedures on an Epics XL (Beckman Coulter). The
single cell suspension was aliquoted and stained with either iso-
type controls or antigen-specific antibodies. Cell surface antigens
were labeled with the combinations of the following monoclonal
antibodies: FITC-, PE-, or biotin- (followed by CyChrome
staining) conjugated H2K
 
b
 
/D
 
b
 
, CD117 (c-kit), CD34, Sca-1,
CD45, CD19, CD11b, and CD3 (BD Biosciences). Dead cells
were excluded from analysis using propidium iodide staining.
Samples were run on an Epics XL flow cytometer and analyzed
with CELLQuest™ software (BD Immunocytometry Systems).
 
In Vitro Hematopoietic Progenitor Assays
 
The single cell suspension of ESC-derived, cytokine-stimu-
lated cells was washed and stained with the following antibodies:
CD45, c-kit, and CD34. The cells were sorted using the gated
dot diagrams in an Epics-Elite ESP flow cytometer cell sorter
(Beckman Coulter). Four different populations of cells were used
for clonal cell culture including CD34
 
  
 
cells (purity 75%), c-kit
 
 
 
cells (purity 63%), CD45
 
  
 
cells (purity 75%), and a heterogeneous
population consisting of CD45
 
  
 
c-kit
 
  
 
(12%), CD45
 
  
 
c-kit
 
 
 
(23%), and CD45
 
  
 
c-kit
 
  
 
(49%) subsets. Cells were plated in pre-
pared methylcellulose-based cultures supplemented with a cock-
tail of growth factors in 35-mm Lux suspension culture dishes
(Nunc) as previously described (17–19). In brief, 200 cells per 1
ml were cultured in medium containing 1.2% methylcellulose,
30% FCS (Hyclone), 1% deionized fraction V bovine serum albu-
min (Sigma-Aldrich), and 5 
 
  
 
10
 
 
 
5 
 
mol/liter 2-mercaptoethanol
(Sigma-Aldrich). The following colony-stimulating factors were
used: 20 ng/ml murine SCF, 10 ng/ml human GM-CSF, 20 ng/
ml human G-CSF, 10 ng/ml murine IL-3, 30 ng/ml murine
IL-6, 3 U/ml human recombinant erythropoietin, and 100 ng/ml
human TPO (StemCell Technologies Inc.). After 12 d of culture
in an incubator at 37
 
 
 
C in humidified atmosphere with 5% CO
 
2
 
,
all colonies were counted under an inverted microscope. The
identification of erythroid burst-forming units (BFU-E), granulo-
cyte-macrophage colonies (CFU-GM/CFU-G/CFU-M/CFU-
Eo), megakaryocyte colony-forming units (CFU-Meg), and
erythrocyte-containing, mixed colony-forming units (CFU-Mix)
colonies was based on the typical morphological features.
 
Enrichment of ESC-derived Hematopoietic Progenitors
 
The suspension of single cells differentiated from ESCs was
collected, washed, and stained with the following antibodies:
CD45 and c-kit. The cells were sorted using an Epics-Elite ESP
flow cytometer cell sorter (Beckman Coulter) as a heterogeneous
population consisting of CD45
 
  
 
c-kit
 
 
 
, CD45
 
  
 
c-kit
 
 
 
, and
CD45
 
  
 
c-kit
 
  
 
subsets. The phenotypic purity of sorted cells de-
termined by postsorting flow cytometry analysis was 86 
 
  
 
11%
for c-kit and 49 
 
  
 
18% for CD45. After sorting, cells were resus-
pended in PBS and used immediately for IBM (10
 
5 
 
cells/30 
 
 
 
l) or
i.v. injection (10
 
6 
 
cells/0.2 ml).
 
Long-Term Repopulation Model
 
Mice.
 
6–7-wk-old female BALB/cJ mice (MHC H2
 
d
 
; Jack-
son ImmunoResearch Laboratories) were used as recipients of
both ESCs and cytokine induced ESCs. Mice were irradiated (to-
tal body irradiation [TBI] 5.5 or 8.0 Gy) 16 h before injection.
The mice were housed in microisolator cages under specific
pathogen-free conditions and provided with 
 
 
 
-irradiated food in
the animal facilities of Northwestern University. All animal ex-
periments were approved by the Institutional Animal Care and
Use Committee of Northwestern University.
 
Transplantation.
 
Cells prepared as described above were in-
jected either i.v. or IBM. i.v. injection was performed into one of
the lateral tail veins. IBM injection was performed according to
the procedure previously described (20). In brief, mice were
anesthetized and after shaving and disinfection, a 5-mm incision
was made on the thigh. The knee was flexed to 90
 
  
 
and the prox-
imal side of the tibia was drawn anteriorly. A 26-gauge needle
was inserted into the joint surface of the tibia through the patellar
tendon and advanced into the bone marrow cavity. Using a 50-
 
 
 
l microsyringe (Hamilton), the cells were injected through the
bone hole and into the bone marrow cavity. The skin was then
closed using 6-0 vicryl sutura (Ethicon).
 
Chimerism.
 
The presence of donor-derived (R1 ESC, H2
 
b
 
) T
lymphoid, B lymphoid, monocytic, and granulocytic lineage was
determined using flow cytometric analysis of mononuclear cells
isolated from peripheral blood of mice 2, 4, 8, 12, and 20 wk after
infusion of ESC-derived cells. Cell surface antigens were labeled
with the following monoclonal antibodies: FITC-, PE-, or bio-
tin-conjugated H2K
 
b
 
/D
 
b
 
, H2
 
d
 
, CD45, CD45R/B220, CD19, 
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CD11b, CD14, and CD3 (BD Biosciences). Mononuclear cells
isolated from the peripheral blood of an untreated BALB/c mouse
were used as a negative control. Mononuclear cells from a 129/Sv
mouse served as a positive control (see Fig. 4, a–c).
 
MLR In Vitro.
 
Immune responses in recipient BALB/cJ
mice toward donor histocompatibility antigen of 129/Sv strain,
recipient MHC, and third party antigens were evaluated by one
way MLR tests. MLR tests were performed in six animals trans-
planted with ESC-derived cells 6 mo after transplantation. 10
 
6
 
splenocytes from chimeric mice were cultured separately in 24-
well plates (Falcon; BD Labware) with 10
 
6 
 
irradiated splenocytes
(30 Gy) obtained from 129/Sv, BALB/cJ, and SJL/J (H2
 
S
 
) mice.
Cells were cultured in a total volume of 2 ml RPMI 1640 me-
dium (Cellgro; Mediatec) supplemented with 2 mM 
 
l
 
-glutamine,
10 mM Hepes, 1 mM sodium pyruvate, 0.1 mM nonessential
amino acids, 50 
 
 
 
g/ml gentamicin, and 10% FSC. After 48 and
72 h of culture in a 37
 
 
 
C humidified CO
 
2 
 
incubator, cells were
pulsed with bromodeoxyuridine (BrdU), adding 20 
 
 
 
g per each
2-ml well as previously described (21). 20 h after the second pulse
of BrdU, cells were harvested and processed with a BrdU Flow
Kit (BD Biosciences) according to the manufacturer’s protocol.
Cells were stained with FITC anti-BrdU and 7-amino-actinomy-
cin. Flow cytometric data were acquired using an Epics XL flow
cytometer and analyzed with CELLQuest™ software. Syngeneic
and allogeneic splenocytes were used as negative and positive
controls, respectively.
 
IFN-
 
  
 
Level Analysis.
 
Spleen cells were isolated from surgi-
cally removed spleen of mice transplanted with ESC-derived
cells and passed over nylon wool columns. 5 
 
  
 
10
 
5 
 
(in 0.2 ml
culture medium) chimeric splenocytes were cultured in pres-
ence of irradiated (30 Gy) donor, recipient, or mismatched
(SJL/J) splenocytes in 96-well plates for 72 h. Culture superna-
tants were collected and levels of IFN-
 
  
 
in supernatants were
determined by ELISA kit according to the manufacturer’s pro-
tocol (R&D Systems).
 
Grading of Histologic Changes of GVHD.
 
All mice were killed
6 mo after ESC-derived transplantation (ESCT). For evaluation
of presence and degree of hepatic and intestinal inflammation, tis-
sues were removed from all mice in both groups and kept in 10%
formaldehyde. Tissue sections were embedded in paraffin, sec-
tioned, and stained with hematoxylin and eosin by standard pro-
cedures. The degree of inflammation of liver and small bowel was
graded in a 0–4 scale as previously described (22).
 
Statistical Analysis
 
All data are presented as the mean 
 
  
 
standard error of the
mean. Two groups of data were analyzed by the Mann-Whitney
U test (Student’s 
 
t
 
 test for nonparametric distribution). P 
 
  
 
0.05
was considered statistically significant.
 
Results
 
Injection of Undifferentiated ESCs.
 
Murine ESCs were
maintained in the undifferentiated state by coculture on ir-
radiated primary fibroblasts in the presence of LIF. Flow
Figure 1. Immunophenotype of undifferentiated
ESCs. Expression of c-kit, CD45 (b), and CD34
and H2b (d) compared with isotype control (a) and
normal murine bone marrow (c). 
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cytometric analysis of undifferentiated ESCs showed the
absence of CD117 (c-kit), CD45, CD34, or MHC mole-
cules on their surface (Fig. 1, a–d). When undifferentiated
ESCs were injected either i.v. or IBM into lethally irradi-
ated mice, marrow/hematopoietic failure resulted in 100%
mortality within 8–13 d (not depicted).
 
Immunophenotype of Ex Vivo Cytokine-stimulated Hemato-
poietic Differentiation of ESCs.
 
To promote ex vivo he-
matopoietic differentiation, undifferentiated ESCs were
cultured in methylcellulose medium by the withdrawal of
LIF and the addition of the hematopoietic cytokines SCF,
IL-3, and IL-6 for 7–10 d resulting in formation of EB.
Flow cytometric analysis of presorted population revealed
that 7% of cultured cells presented the HSC marker c-kit
and 
 
 
 
5% presented the panleukocytic marker CD45 (Fig.
2, a and b). The immunophenotype of c-kit
 
  
 
CD45
 
  
 
ESC-
derived progenitor cells is Sca-1
 
  
 
(Fig. 2 c), H2
 
b
 
  
 
(Fig. 2
d), and lineage
 
  
 
for B cell marker B 220 (Fig. 2 f), mono-
Figure 2. Immunophenotype of cy-
tokine-stimulated ESCs. Percent of
cytokine-stimulated ESCs that are c-kit 
(a) and CD45  (b) cells. Immunopheno-
typic characteristics of ESC-derived cells
sorted for dual c-kit  CD45 : Sca-1 
and c-kit   (c), H2b   and c-kit   (d),
CD45  and c-kit  (e), and Lin  (f–h). 
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899
cytes/granulocytes marker CD11
 
b 
 
(Fig. 2 g), and red blood
cell marker Ter119 (Fig. 2 h).
 
In Vitro Colony-forming Unit Formation of Cytokine-stimu-
lated ESCs.
 
The in vitro ability of cytokine-stimulated
ESCs to form hematopoietic colonies was investigated
from sorted ESC-derived hematopoietic progenitor cells
expressing either CD34, c-kit, CD45, or both c-kit and
CD45. Enriched by flow cytometry, cell subsets were
plated in prepared methylcellulose-based cultures supple-
mented with SCF, IL-3, IL-6, and/or recombinant ery-
thropoietin. Total progenitor frequency of colony-forming
units CFU-GM, BFU-E, CFU-Meg, and CFU-Mix, was
scored after 12 d of culture (Fig. 3 a). The highest plating
efficiency from cytokine-stimulated ESCs was observed
with dual positive c-kit
 
  
 
CD45
 
  
 
cells that formed the larg-
est number of CFU-GM, BFU-E, CFU-Meg, and CFU-
Mix colonies (Fig. 3 a).
 
In Vivo Injection of Cytokine-stimulated ESCs.
 
i.v. injec-
tion of nonsorted cytokine differentiated ESCs into lethally
irradiated mice did not result in hematopoietic reconstitu-
tion leading to death of all (
 
n 
 
  
 
7) mice between days 8–13
(Fig. 3 b). In the case of IBM injection of nonsorted cyto-
kine-differentiated ESC suspensions, hematopoiesis was re-
constituted with a low percentage of donor-mixed chimer-
ism (2–12%; not depicted), however, in two out of seven
mice, teratomas that were confirmed histologically arose at
the IBM injection site (Fig. 3 b).
As already mentioned, the largest number of ex vivo
hematopoietic colonies of myeloid, erythroid, and mega-
karyocytic lineages arose from cytokine-stimulated ESCs
that were enriched for c-kit
 
  
 
and CD45
 
  
 
(Fig. 3 a). Based
on our in vivo hematopoietic colony-forming assay re-
sults and observations by McKinney-Freeman et al. (23)
and Cho et al. (24), we chose two immunophenotypic
markers to purify hematopoietic progenitors derived from
ESCs. Therefore, ESC-derived c-kit /CD45   HSCs
were isolated by flow cytometry and injected either i.v.
(106 cells in 0.2 ml) or IBM (0.5   105 cells in 15  l   2)
into irradiated (TBI 5.5 or 8.0 Gy) 6–7-wk-old BALB/c
mice (MHC H2d; Fig. 3 b). The sorted cell population
Figure 3. Cytokine-stimulated ESCs ex vivo
and in vitro analysis data. (a) Efficiency of hemato-
poietic colony formation by 200 ESC-derived
cells (different population: enriched for c-kit ,
c-kit  CD45 , and CD34 ). (b) Survival curve
for mice injected i.v. with nonsorted ESC-derived
cells, IBM injected with nonsorted ESC-derived
cells, and injected i.v. or IBM with sorted c-kit 
CD45  cells. (c) Mean percentage of donor chi-
merism in different groups of mice analyzed 2,
4, 10, and 20 wk after ESCT. IBM-5.5, irradiated
with 5.5 Gy, injected IBM; IBM-8, irradiated
with 8.0 Gy, injected IBM; i.v.-8, irradiated with
8.0 Gy, injected i.v.ESCs As an Alternate Marrow Source 900
prepared for injection was analyzed by flow cytometry
and immunophenotypically was 86   11% c-kit , 49  
18% CD45 , 80–84% Sca-1 ,   90% H2b , and Lin 
(Fig. 2, c–h).
The earliest reconstitution from ESC-derived HSCs
(MHC H2b) was observed after 2 wk, at which time the
percentage of anti-H2Kb/Db /CD45  cells was 20.3  
14.0% (Table I and Figs. 3 c and 4, a–c). By 4 wk after
ESC-derived HSC injection, the population of H-2b /
CD45  cells increased to 34.4   22.4%. Analysis of chi-
merism performed 6 mo after transplantation showed a fur-
ther increase of ESC-derived hematopoiesis to 49.0  
31.1% (range: 7.9–95.5%; Table I and Fig. 3 c).
Mice irradiated with 8.0 Gy before IBM injection of
ESC-derived c-kit /CD45  HSCs had a higher percentage
of donor chimerism compared with mice irradiated with a
less immune suppressive dose of 5.5 Gy (Table I and Fig. 3
c). When comparing TBI 8.0 to 5.5 Gy, percent donor en-
graftment was 30.4   11.8 versus 9.2   4.2 (P   0.05) at 2
wk and 73.7   17.6 versus 30.1   13.4 (P   0.05) at 20
wk, respectively (Table I and Fig. 3 c). Mice injected IBM
compared with the i.v. route of administration had faster
and more effective reconstitution of hematopoiesis from
ESC-derived hematopoietic progenitor cells. Between
IBM and i.v. routes of administration, the percent donor
engraftment was 30.4   11.8 versus 8.7   2.6 at 2 wk
(P   0.05) and 73.7   17.6 versus 12.1   4.7 (P   0.01)
at 20 wk, respectively (Table I and Fig. 3 c). Flow cyto-
metric analysis of PBMC subpopulations revealed that the
population of donor-derived T lymphocytes (H-2b /CD3 
cells) comprised 18.3   4.7 and 17.3   6.5% of PBMC at
10 and 20 wk, respectively (Fig. 4, f and g). The population
of H-2b /CD14 /CD11b  (monocytes/granulocytes) was
47.3   16.5% at 10 wk after transplantation and remained
stable for a maximum follow-up of 24 wk (Fig. 4, f–h).
Reconstitution of chimeric B lymphocytes (H-2b /CD19 
cells) was 3.1   3.4% at 20 wk (Fig. 4, f and g). No mouse
receiving sorted cells developed a teratoma or had evidence
of malignant or abnormal growth.
Immunologic Competence of ESC-derived Hematopoiesis.
No mouse developed runting (ruffled fur, hunched back,
and weight loss) consistent with GVHD despite stable
MHC-mismatched engraftment. There was no histologic
evidence of GVHD in autopsy specimens of liver or bowel.
MLRs were evaluated by means of BrdU incorporation
using splenocytes from chimeric, 129/Sv (ESC donor),
BALB/c (recipient), and SJL/J (third party) mice. Spleno-
cytes collected from chimeric mice were characterized by
low MLR proliferative responses to cells of either the donor
or host MHC compared with proliferative responses to SJL/J
(third party, MHC-mismatched) splenocytes (9.2   2.1,
5.6   3.4, and 24.3   9.1%, respectively; Fig. 5 a). IFN- 
production from chimeric mice correlated with the MLR
results (Fig. 5 b) in that there was an inverse correlation be-
tween percentage of donor chimerism and either prolifera-
tive response or IFN-  production against donor genotype
MHC splenocytes (R    0.89 and R    0.87, P   0.01,
respectively; Fig. 5, c and d). The highest IFN-  production
Table I. Mixed Chimerism in Mice Transplanted with ESC-derived c-kit /CD45  Cells Analyzed in Different Time Points after Injection
Mouse TBI Injection of ESCs Chimerism at 2 wk Chimerism at 4 wk Chimerism at 10 wk Chimerism at 20 wk
Gy
1 5.5 IBM 9.1 3.1 14.0 27.5
2 5.5 IBM 3.4 28.5 27.6 34.3
3 5.5 IBM 13.2 34.5 47.2 45.3
4 5.5 IBM 11.0 21.3 12.1 13.2
5 8.0 IV 5.7 6.0 10.1 9.5
6 8.0 IV 7.3 12.0 15.1 7.9
7 8.0 IV 11.3 8.7 11.0 12.5
8 8.0 IV 10.5 23.5 20.3 18.6
9 8.0 IBM 22.3 61.5 62.0 87.3
10 8.0 IBM 17.7 46.0 51.5 45.7
11 8.0 IBM 27.6 29.3 68.3 91.0
12 8.0 IBM 33.8 63.0 59.0 57.0
13 8.0 IBM 18.9 73.0 93.0 74.3
14 8.0 IBM 35.6 34.7 75.3 56.0
15 8.0 IBM 54.7 72.1 63.4 85.6
16 8.0 IBM 23.7 25.7 68.1 71.2
17 8.0 IBM 39.0 42.3 79.1 95.5
Data are presented as percent of H2Kb /CD45  cells.Burt et al. 901
against irradiated third party (SJL/J) splenocytes achieved
levels of positive controls (mismatched splenocytes; 1,674.9  
534.7 and 2,024.3   234.5, respectively; Fig. 5 b), indicat-
ing an intact immune response to foreign antigens.
Discussion
Most of the data concerning ESC-derived differentiation
is based on in vitro studies (11, 12, 16, 24–27). The ques-
tion of whether hematopoietic progenitors derived in vitro
from mouse ESCs can support in vivo long-term multilin-
eage engraftment remains unanswered (15, 28). Previous
reports suggest that ESCs or cells derived from ESCs have a
limited capacity to engraft and reconstitute hematopoiesis
in vivo (15). It has been shown that ESCs transduced with
a retrovirus containing the BCR/ABL oncogene differen-
tiated in vivo into multiple myeloid cell types as well as T
and B lymphocytes (29). Some components of hemato-
poiesis have also been reconstituted in immune-deficient
mice, e.g., SCID or RAG-1–deficient mice (11, 30, 31).
However, it has not been previously demonstrated that ge-
netically normal (i.e., nontransduced) ESCs or cells derived
from ESCs are capable of reconstituting an intact and func-
tional immune system in normal mice. Our data confirmed
failure of hematopoietic engraftment from undifferentiated
ESCs. Either i.v. or IBM injection of undifferentiated
ESCs into lethally irradiated mice results in 100% mortality
from marrow failure. Our findings also demonstrated either
no or marginal hematopoietic engraftment and/or teratoma
formation after injection of a nonpurified heterogeneous
Figure 4. Immunophenotype of peripheral blood
after ESCT. Comparison of percentage of H2b 
leukocytes in peripheral blood of the C57BL/6J
mouse (a), BALB/c mouse (b), and chimeric
BALB/c mouse 2 wk after ESC-transplantation
(TBI 8.0 Gy/TBI; c). Example of analysis of chi-
merism based on immunophenotyping of PBMCs
in two channels: H2b  (donor-derived) and H2d
(host-derived) and CD45  (10 wk after ESCT; TBI
8.0 Gy/TBI; d and e). Analysis of H2b  mononuclear
cells in peripheral blood from chimeric mouse (20
wk after ESCT; TBI 8.0 Gy/IBM): gating (H
gate) positive population H2b  (f) and analysis
of percent of T lymphocytes (CD3 ), B lympho-
cytes (CD19 ; g), and granulocytes/monocytes
(CD11b /CD14 ; h).ESCs As an Alternate Marrow Source 902
population of cells derived from cytokine-stimulated ESCs.
i.v. injection of a cytokine-differentiated, nonsorted ESC
suspension resulted in 100% mortality, whereas IBM injec-
tion resulted in only low level chimerism ( 12%) and in
some mice, formation of teratomas at the IBM site. How-
ever, we observed that when ESCs, induced to differentiate
ex vivo into hematopoietic precursors and sorted for c-kit 
and CD45  cells, are injected, rapid hematopoietic and im-
mune reconstitution occurs from the ESC donor without
development of teratomas.
In this report, ESCs generated EB ex vivo containing
hematopoietic precursors in methylcellulose cultures, con-
sistent with previous findings (12, 32). Previous data sug-
gests that multipotent, long-term, repopulating hematopoi-
etic progenitors might be formed within EB around day 4
after LIF withdrawal (29) and that SCF and CD45 recep-
tors arise around day 8 of EB culture (15). Miyagi et al. (30)
reported that ESCs express low levels of the c-kit receptor
on their surface, whereas Hole et al. (15) reported that ex-
pression of c-kit is absent in ESCs until day 8 of EB cul-
ture. In agreement with Hole et al., we found no expres-
sion of c-kit on undifferentiated ESCs. C-kit expression
appeared between days 6 and 8 of ESC culture in methyl-
cellulose medium (unpublished data). To avoid undifferen-
tiated cells that may generate teratomas as well as unwanted
excessive differentiation of ESCs into more mature stages,
we harvested cells that had been cultured for 7–10 d. As
there is no consensus regarding the immunophenotypic
features of murine ESC-derived HSCs, we chose the phe-
notypic markers c-kit/CD45 for the purification based on
Figure 5. Immunologic competence of ESC-derived
hematopoiesis. (a) Proliferative response of splenocytes
from chimeric mice to donor and recipient MHC and
third party antigen (data are presented as a percent of
BrdU incorporated cells). (b) Production of IFN-  during
MLR analyzed by ELISA (mean values). (c) Correla-
tions between donor chimerism analyzed at 20 wk after
transplantation and proliferative response to donor
MHC (analyzed by MLR) and (d) IFN-  level assessed
by ELISA in MLR (donor and chimeric splenocytes)
supernatant. Proliferative response as well as IFN- 
data are presented in log scale, whereas chimerism is
shown as the percentage of donor (ESC-derived) cells
in peripheral blood in linear scale.Burt et al. 903
in vitro colony-forming assay that found inclusion of the
CD45  cell population along with c-kit  cells results in
more efficient in vitro functionality. Other reports have
suggested that sorting for CD41 and c-kit expression may
result in better enrichment of definitive hematopoietic pro-
genitors (33, 34).
Analysis of cell population sorted for CD45/c-kit cells
(enriched, but not clonal) revealed enrichment for cells
expressing the murine HSC marker Sca-1 as well as lack-
ing lineage-specific markers. To this date, the identifica-
tion and true clonal phenotype of human HSCs remains
elusive. For this reason, clinical human stem cell trans-
plants that result in long-term engraftment use a nonclonal
but enriched population of marrow or blood cells selected
for progenitor markers such as CD34 or CD133. Our data
demonstrate that ESC-derived hematopoietic progenitor
cells (enriched, but nonclonal) also result in stable, long-
term hematopoietic engraftment.
ESCs are allogeneic cells that are immunologically and
genetically distinct from the recipient. However, hemato-
poietic reconstitution of ESC-derived T lymphocytes, B
lymphocytes, and monocytes occurred across MHC barri-
ers without evidence of rejection. The percentage of ESC-
derived hematopoiesis was greater after IBM injection
compared with i.v. injection despite 1 log fewer cells be-
ing injected IBM compared with i.v. Our results with
ESC-derived hematopoietic progenitor cells are similar to
the findings of Kushida et al. (20), Ikehara (35), and Wang
et al. (36), who first demonstrated superior engraftment
with IBM injection compared with i.v. injection from
adult HSCs. These findings suggest that homing of stem
cells to the marrow might be inefficient with the i.v. route
of administration.
It has been observed that preimplantation-derived, em-
bryonic-like stem cells when injected into liver via the por-
tal vein are able to induce tolerance (37). Several explana-
tions of this phenomenon were proposed including low
MHC class I expression, incomplete hematopoietic chi-
merism with restriction of T and NK cell populations, and
successful posttransplant thymic reeducation of T cells (37).
In our animal model, after injection of ESC-derived he-
matopoietic progenitors into either the systemic circulation
or IBM, we observed multilineage hematopoietic engraft-
ment. The ESC-derived T cells were bidirectionally toler-
ant to recipient and host because MLC proliferative
responses to recipient and host lymphocytes were dimin-
ished. This is consistent with both engraftment and absence
of clinical or histologic evidence of GVHD in autopsied
tissues. Importantly, immune competence was maintained,
as demonstrated by healthy mice without infections and
normal third party MLC proliferative responses and IFN- 
production.
Although some groups have previously shown transplan-
tation of ESC-derived blood cells, engraftment was brief
and/or deficient in several lineages. Our data demonstrate
that ESC-derived cells enriched for a population of c-kit 
CD45  hematopoietic progenitors may reconstitute long-
term multilineage hematopoiesis with a functional immune
system and without GVHD. Future studies will focus on
clonal analysis of ESC-derived progenitors responsible for
long-term hematopoietic engraftment.
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